BioCentury
ARTICLE | Product Development

Kymera adds to the clinical picture for protein degraders 

The company digs into the biological effects of its IRAK4 degrader

October 28, 2021 12:51 AM UTC

The latest clinical data from Kymera adds to the growing body of evidence that targeted degraders are effective at depleting proteins in humans, and gives a fuller picture of downstream biological effects.

At the 4th Annual Targeted Protein Degradation Summit on Wednesday, Kymera Therapeutics Inc. (NASDAQ:KYMR) presented data from its Phase I trial of KT-474 in healthy volunteers, the first randomized, double-blind, placebo-controlled trial for a protein degrader. The trial will recruit up to 20 patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS) in 1Q22, with a data readout expected mid-year. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article